Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 17INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 38Genitourinary 21Gynecologic 17Head & Neck 16Thoracic 13Dermatologic 10Tumor-Agnostic 8Other solid neoplasm 6CNS 4Breast 4Sarcoma 3Lymphoid 3Endocrine 2Other hematologic neoplasm 1

Conditions

Thyroid Carcinoma, Anaplastic 1Differentiated Thyroid Cancer (DTC) 1

Interventions

Everolimus 23pasireotide 14lutetium Lu 177 dotatate 10Octreotide 10lanreotide 9surufatinib 8Carboplatin 8Paclitaxel 7pembrolizumab 5amino-acid, glucose, and electrolyte solution 5Thyrotropin Alfa 5Sunitinib 5Nivolumab 5Injections 53-Iodobenzylguanidine 5relacorilant 4fosbretabulin 4Temozolomide 4Fulvestrant 4Etoposide 4Data Collection 4Cisplatin 4vandetanib 3selpercatinib 3dabrafenib 3anlotinib 3Mifepristone 3Lutetium-177 3Lutetium 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × lenvatinib × Endocrine × Clear all
NCT02966093 2022-01-26

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Eisai Inc.

Phase 3 Completed
151 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

NCT02657369 2019-10-15

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Eisai Inc.

Phase 2 Terminated
34 enrolled 13 charts
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡